Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)

Journal of Neuro-oncology
John D HainsworthKent C Shih

Abstract

Current bevacizumab-based regimens have failed to improve survival in patients with recurrent glioblastoma. To improve treatment efficacy, we evaluated bevacizumab + BKM120, an oral pan-class I PI3K inhibitor, in this patient population. A brief phase I study established the optimal BKM120 dose to administer with standard-dose bevacizumab. BKM120 60 mg PO daily + bevacizumab 10 mg/kg IV every 2 weeks in 28-day cycles was then administered to patients with relapsed/refractory glioblastoma in the phase II portion. Eighty-eight patients enrolled (phase I, 12; phase II, 76). In phase I, BKM120 80 mg PO daily produced dose limiting toxicity in 3 of 6 patients; a BKM120 dose of 60 mg PO daily was established as the maximum tolerated dose. In phase II, the median progression-free survival (PFS) was 4.0 months (95% CI 3.4, 5.4), PFS at 6 months was 36.5%, and the overall response rate was 26%. Forty-two patients (57%) experienced one or more serious treatment related toxicities. The most common CNS toxicities included mood alteration (17%) and confusion (12%); however, these were often difficult to classify as treatment- versus tumor-related. The efficacy seen in this study is similar to the efficacy previously reported with single-age...Continue Reading

References

Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Sep 15, 2001·Journal of General Internal Medicine·K KroenkeJ B Williams
May 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arnab ChakravartiJay S Loeffler
May 24, 2006·Archives of Internal Medicine·Robert L SpitzerBernd Löwe
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James J VredenburghHenry S Friedman
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenSusan M Chang
May 25, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John F de GrootPatrick Y Wen
Oct 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Todd W MillerCarlos L Arteaga
Dec 14, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Johanna C BendellJosé Baselga
Dec 23, 2011·Molecular Cancer Therapeutics·Sauveur-Michel MairaCharles F Voliva
Feb 13, 2013·Nature Reviews. Clinical Oncology·Jordi RodonJosep Tabernero
Aug 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tracy T BatchelorMartin van den Bent
Feb 7, 2014·Journal of Cancer Research and Clinical Oncology·Phyllis R WachsbergerAdam P Dicker
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
Mar 26, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ingrid A MayerCarlos L Arteaga
Sep 27, 2014·BMC Cancer·Fonnet E BleekerAlberto Bardelli
Nov 6, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Debashis SarkerJohann S de Bono
Nov 16, 2017·The New England Journal of Medicine·Wolfgang WickMartin J van den Bent
Feb 5, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenKeith L Ligon

❮ Previous
Next ❯

Citations

Apr 16, 2020·Cancers·Vilashini RajaratnamShama Parveen Mirza
Mar 19, 2020·OncoTargets and Therapy·Zhijie TanShanshan Liu
Oct 16, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Hyeon Ji Kim, Do-Yeon Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.